Table 2.

Accuracy of the 4-Gene Signature in Vedolizumab and Anti-TNF–Treated Patients

	Discovery dataset RNA-seq (n = 20; 9 NR, 11 R)	Validation dataset 1 RNA-seq (n = 11; 3 NR, 8 R)	Validation dataset 2 RNA-seq (n = 16; 11 NR, 5 R)	Validation dataset 3 Microarray (n = 13; 9 NR, 4 R)	Anti-TNF dataset RNA-seq (n = 20; NR 12, R 8)
Accuracy, %	80.0	100.0	81.3	76.9	55.0
Sensitivity, %	81.8	100.0	66.7	100.0	75.0
Specificity, %	77.8	100.0	90.0	70.0	41.7
Positive predictive value, %	81.8	100.0	80.0	50.0	46.2
Negative predictive value, %	77.8	100.0	81.8	100.0	71.4
Positive likelihood ratio	3.7	∞	6.67	3.3	1.3
Negative likelihood ratio	0.2	0	0.3	0	0.6

NR, nonresponder; R, responder; RNA-seq, RNA sequencing; TNF, tumor necrosis factor.